Navigation Links
Dr. Robert J. Rubin to Join Halt Board as Reimbursement Advisor
Date:7/26/2010

LIVERMORE, Calif., July 26 /PRNewswire/ -- Halt Medical, Inc. announced today that Robert J. Rubin, M.D. has been appointed to its Scientific Advisory Board.  Dr. Rubin will also be a consultant to the company, helping to develop and implement comprehensive reimbursement strategies.  Dr. Rubin's distinguished career has included significant contributions in the fields of medicine, government, and business. Currently, he is Clinical Professor of Medicine at Georgetown University's School of Medicine and serves as a consultant to several international healthcare companies. Among his positions in government, Dr. Rubin served as Assistant Secretary, U.S. Department of Health and Human Services (DHHS), concurrent with his appointment as Assistant Surgeon General from 1981 to 1984.  Among his positions in business, Dr. Rubin served as president of the leading healthcare consulting firm, The Lewin Group, Inc., and its predecessor organizations, from 1987 to 2001.

"Dr. Rubin brings to Halt Medical significant medical and business expertise", commented Jeff Cohen, Halt's Chief Executive Officer.  "While Dr. Rubin was at the DHHS, he was responsible for passage of Medicare's Prospective Payment System.  His guidance will add significant value to Halt, particularly in the areas of public and private sector reimbursement strategies for the Halt Fibroid Procedure".  

About Halt Medical, Inc.

Halt Medical, Inc. is a late-stage medical device design and manufacturing company developing products to ablate tissue with its next generation Radiofrequency Volumetric Thermal Ablation (RFVTA) system.  The Halt system has been cleared by the FDA for general use and is currently being studied in the US for relief of symptoms caused by uterine fibroids.  Halt is preparing to commercialize the Halt Fibroid System in Europe where it has recently obtained the CE mark for general and fibroid indications.  The worldwide business opportunity for the Halt Fibroid System is estimated to be over $2 billion annually.  

Information about the Halt Fibroid Study and a list of clinical sites in the U.S. may be found at

www.clinicaltrials.gov, study number NCT00874029.


'/>"/>
SOURCE Halt Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Franco Nuschese Tapped by Robert C. Gallo Foundation for AIDS and Virus Research
2. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
3. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
4. Veridiam Names Robert Mazzacavallo New CFO
5. Wound Management Technologies Completes Acquisition of Secure eHealth, LLC and Other Assets from VirtualHealth Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
6. VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
7. Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position
8. Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo
9. Dr. Robert B. Arnot Releases White Paper on the Silent Threat of H1N1 and Other Infectious Diseases
10. PolyTouch Medical Ltd. Announces the Appointment of Robert D. Fanelli, MD, FACS, FASGE as Medical Advisor
11. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):